Pages that link to "Q54304254"

The following pages link to Phase I study of XL281 (BMS-908662), a potent oral RAF kinase inhibitor, in patients with advanced solid tumors. (Q54304254):

Displaying 11 items.

• High-throughput drug library screening identifies colchicine as a thyroid cancer inhibitor (Q35945841) (← links)
• Simultaneous dual targeting of Par-4 and G6PD: a promising new approach in cancer therapy? Quintessence of a literature review on survival requirements of tumor cells (Q37417255) (← links)
• Targeting RAS-mutant cancers: is ERK the key? (Q38267209) (← links)
• Stamping out RAF and MEK1/2 to inhibit the ERK1/2 pathway: an emerging threat to anticancer therapy. (Q38585847) (← links)
• The Future of Molecular Analysis in Melanoma: Diagnostics to Direct Molecularly Targeted Therapy (Q38620826) (← links)
• Update on Metastatic Uveal Melanoma: Progress and Challenges. (Q38783505) (← links)
• Current Status and Perspectives Regarding LNA-Anti-miR Oligonucleotides and microRNA miR-21 Inhibitors as a Potential Therapeutic Option in Treatment of Colorectal Cancer (Q38841033) (← links)
• The Treatment of Advanced Thyroid Cancer in the Age of Novel Targeted Therapies (Q38865611) (← links)
• The NF1 gene in tumor syndromes and melanoma (Q39076849) (← links)
• Fortunellin-Induced Modulation of Phosphatase and Tensin Homolog by MicroRNA-374a Decreases Inflammation and Maintains Intestinal Barrier Function in Colitis (Q50284482) (← links)
• A cancer drug atlas enables synergistic targeting of independent drug vulnerabilities (Q96303348) (← links)